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Background:  Recent  clinical  evidence  indicates  that  an intradermal  (ID)  delivery  of vaccines  confers
superior  immunogenicity  as compared  to a standard  intramusclular  or  subcutaneous  (SC)  delivery.
Methods:  In this  exploratory  study,  600  healthy  adults  were randomized  to 6 study  groups  with subgroups
of  young  adults (20–64  years  old)  and  older  adults  (65  years  and  older).  The  subjects  were  either  injected
by  a novel  ID  injection  system  with  a  single  dose  of 6, 9, or 15  g  HA or two  doses  (21 days  apart)  of
15  g HA  per  strain  or injected  by  an  SC  injection  method  with  a single  or two  doses  (21  days  apart)
of  15 g HA  per  strain.  Immunogenicity  was  assessed  using  hemagglutination  inhibition  (HAI) titer  and
microneutralization  titer  on  Days  0,  10,  21,  and  42.  Solicited  and  unsolicited  adverse  events  were  recorded
for 7 and  21  days  post-vaccination,  respectively.
Results:  In both  young  adults  and  older  adults  groups,  the  geometric  titer  (GMT)  ratios  of  HAI  in the  ID
15  g HA  group  were  higher  than  those  in the  SC  15 g HA  group  on both  Day  10 and  Day  21,  while  those
in  the  ID 6  and  ID 9 g HA  groups  were  comparable  with  those  in  the  SC 15  g  HA group.  The  kinetics
of GMTs  of HAI  suggested  that  the ID  vaccine  has  the potential  to induce  the prompt  immune  response,
which  is rather  hampered  in  older  adults  as seen  in  the  SC  vaccine  groups.  The  injection-site  AEs  were
generally  mild  and transient,  and  did  not  occur  in  a dose  or dosage-dependent  manner.
Conclusions:  The  results  of this  study  clearly  suggest  that the  immunologic  proﬁle  of  the  ID  vaccine  is  better
than  that  of  the  SC  vaccine,  while  the  safety  proﬁle  of  the  ID vaccine  is similar  to  that of  the  SC vaccine.
In  this  exploratory  study  with  almost  100  subjects  per  each  group,  single  or two-dose  administration
of  the  ID  vaccine  containing  15 g HA was  suggested  to be an  appropriate  regimen  in  order  to  prevent
inﬂuenza  and  to reduce  the  associated  disease  burden.
Trial registration:  JAPIC  Clinical  Trials  Information  (JapicCTI-132096).
ublis© 2015  The  Authors.  P
. Introduction
Inﬂuenza remains a signiﬁcant cause of morbidity and mortality
orldwide, resulting in a major public health concern. Despite pre-
entive efforts, seasonal inﬂuenza virus infections are estimated to
ause 3–5 million cases of severe illness and up to 250,000–500,000
eaths every year worldwide [1]. It is still difﬁcult to control
Abbreviations: ID, intradermal; SC, subcutaneous; HA, hemagglutinin; HAI,
emagglutination inhibition; NT, microneutralization; GMT, geometrical mean
iter; GMTR, GMT  ratio; SCR, seroconversion ratio; SPR, seroprotection ratio; AE,
dverse event; CHMP, The Committee for Medicinal Products for Human Use.
∗ Corresponding author at: Vaccine Business Oversight Department, Daiichi
ankyo Co. Ltd., 3-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, Japan.
el.: +81 80 1310 8663.
E-mail address: Takeshita.fumihiko.aw@daiichisankyo.co.jp (F. Takeshita).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.010
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
inﬂuenza outbreaks, epidemics, and/or pandemics, because of the
nature of inﬂuenza viruses, such as the antigenic drift occurring
every season, changes of host/tissue tropism from natural reser-
voirs, i.e. transmission from swine and/or birds to humans, and the
high transmissibility due to the short incubation period to repro-
duce infectious viruses [2].
In order to prevent from inﬂuenza virus infection and to reduce
the burden of inﬂuenza-associated diseases, vaccination strategies
have been implemented and cover children 6 months and older,
adolescents, young adults, and the elderly [1]. Standard inﬂuenza
vaccines currently used contain the tri- or quadri-valent hemag-
glutinin (HA) antigen derived from inactivated inﬂuenza virus and
are administered either intramuscularly (IM) or subcutaneously
(SC), the latter being used exclusively in Japan. The number of
doses and dosage of vaccines vary depending on the age, under-
lying diseases, and conditions of the vaccinee [1]. In Japan, the
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ecommended number of doses for the seasonal inﬂuenza vaccine
s one or two doses for 13 years and older. Among target popula-
ions, the elderly, in general, need to securely acquire the protective
mmunity because they are more vulnerable to death and hospital-
zation due to inﬂuenza and at higher risk of deterioration from
nderlying diseases upon inﬂuenza infection as compared with
ealthy young adults [1]. Standard inﬂuenza vaccines have, how-
ver, a lower immunogenicity in the elderly than in young adults
3].
In order to improve inﬂuenza vaccine efﬁcacy, various
pproaches have been made over decades, including the change of
dministration route, i.e., intradermal, transdermal, or intranasal
oute, and the change of formulation, i.e., addition of new adju-
ants, an increase of the antigen dosage, or the usage of different
ntigen types. Among these, it has been clinically demonstrated
hat inﬂuenza vaccines delivered by several different types of intra-
ermal (ID) injection and those formulated with a novel adjuvant
ave unique proﬁles in immunogenicity and usability superior to
he standard ones and some of such products have been introduced
nto the market since the late 2000s [4–6].
Accumulating evidence has indicated that the immunogenicity
f vaccines is modulated depending on the route of administra-
ion. ID vaccination has the advantages of immunogenicity, safety,
olerability, and acceptability over IM or SC vaccination [4,7]. In
act, as a dose-sparing, the World Health Organization (WHO) rec-
mmend the ID administration of a reduced dosage of the rabies
accine originally used for the IM injection with an expectation
o improve vaccination coverage for post-exposure prophylaxis in
ow-income countries [8]. However, thus far, the ID delivery has
een used as a route for limited licensed vaccines, including Bacillus
almette–Guérin (BCG) for tuberculosis and a new type of inﬂuenza
A vaccine with an injection device speciﬁcally for the ID delivery
4,7].
The accuracy and the consistency of an ID administration by
he Mantoux technique with a standard syringe and needle mostly
epend on the performance of the practitioner. In order to offer a
imple, accurate, consistent, and safe ID administration, several dif-
erent devices speciﬁcally for the ID injection have been developed
4,9–12].
In this exploratory dose-ﬁnding study, we  investigated the
mmunogenicity and safety of two different numbers of doses (sin-
le and two-dose) and three different dosages (6, 9, and 15 g HA
er dose) of the inﬂuenza vaccine with the novel ID injection sys-
em (Immucise®, Terumo Co., Tokyo, Japan) by comparing it with
he standard SC vaccine (15 g HA per dose). As a result, we have
ecided the number of doses and dosage of the novel ID vaccine
ppropriate for clinical use and will further examine its efﬁcacy
nd safety proﬁle in the conﬁrmatory studies and its application
or infants and adolescents.
. Materials and methods
.1. Study design and objectives
This phase 1/2, randomized, active control, parallel-group study
as conducted at four centers in Japan in 2013. The objective of this
tudy was an evaluation of the number of doses and dosage of the
ovel ID vaccine by comparing it with the standard SC injection
ype seasonal inﬂuenza vaccine in healthy adults aged 20 years old
nd older.
The randomization lists were prepared by using a permuted
lock randomization method. Six hundred subjects were random-
zed at an equal ratio to the four different groups for the ID vaccine
single-dose of 6, 9, or 15 g HA and two-dose of 15 g HA) and the
wo different groups for the SC vaccine (single-dose or two-dose3 (2015) 6340–6350 6341
of 15 g HA). The ratio of 20- to 64-year-old subjects (Young Adult
subgroup) to 65 years and older subjects (Older Adult subgroup)
was 1:1 in each vaccine group. The ID vaccine groups of single-dose
6, 9, and 15 g HA were double-blinded.
On Day 0, blood was  taken and then the ﬁrst vaccination was
conducted in all groups. On Day 10 (7–13 days after the ﬁrst vac-
cination), blood was taken in the single-dose groups. On Day 21
(14–28 days after the ﬁrst vaccination), blood was taken in all
groups and then the second vaccination was conducted in the two-
dose groups. On Day 42 (14–28 days after the second vaccination),
blood was  taken in the two-dose groups. The appearance of shock
and anaphylaxis was  checked in all groups up to 30 min  after each
vaccination.
This study was approved by the institutional review boards of
each study center. The study was  conducted in accordance with
Good Clinical Practice and the Declaration of Helsinki. Written
informed consent was  obtained from all subjects before enrollment.
2.2. Subjects
Healthy Japanese adults aged 20 years and older were eligible to
participate in this study. The main exclusion criteria included: any
history of seasonal inﬂuenza in the past six months, any history of
seasonal inﬂuenza vaccination in the past six months, an axillary
temperature ≥37.5 ◦C, severe acute illness, any history of intoler-
ance or anaphylaxis to the study vaccine components or the ID
injection system, and past medical history of diseases which were
described as severe AEs (e.g. acute disseminated encephalomyelitis
and thrombocytopenia purpura).
2.3. Vaccines
All vaccines contain inactivated, trivalent, split-virion
inﬂuenza hemagglutinin (HA) derived from A/California/7/2009/
(H1N1)pdm09, A/Victoria/361/2011(H3N2), and B/Wisconsin/
1/2010 vaccine strains recommended by the Ministry of Health,
Labor, and Welfare in Japan for the 2012/13 season. All vaccines
were manufactured by using embryonated eggs at Kitasato Daiichi
Sankyo Vaccine Co., Ltd (Saitama, Japan). The ID vaccine was
administrated with a dose of 0.1 mL  containing 6, 9, or 15 g of
HA per strain per dose using the ID injection system (Immucise®,
Terumo Co., Tokyo, Japan). The ID injection system consists of a
needle assembly with a single 33-gauge needle and a syringe. As
a control, the licensed inﬂuenza vaccine was  administered as an
SC dose of 0.5 mL  containing 15 g of HA per strain per dose. The
ID vaccine was  administrated in the deltoid area of the upper arm,
while the SC vaccine was  administrated into an extensor side of
the upper arm.
2.4. Immunogenicity assessment
Immunogenicity was assessed using hemagglutination inhibi-
tion (HAI) titers and microneutralization (NT) titers in a blinded
manner. HAI titers were measured by using turkey red blood cells,
while NT titers were measured by using each vaccine strain of
inﬂuenza viruses. Both antibody titers were measured at VisMed-
eri srl (Siena, Italy). HAI titer was deﬁned as the reciprocal of
the highest dilution at which hemagglutin (HA) activity was
totally inhibited. The titer of each sample was calculated as the
average of its duplicate. NT titers were determined as the recip-
rocal of the serum dilution at which at least 50% inhibition of
cytopathogenic effect was achieved, and then calculated accord-
ing to the Spearman-Kärber formula. Based on the criteria for
seasonal inﬂuenza vaccine of The Committee for Medicinal Prod-
ucts for Human Use (CHMP), immunogenicity was  assessed based
on the geometric mean titer (GMT) of HAI, the seroprotection
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ID 6 μg 1 do se
Day 0 vaccinated : 100
(20-64y: 50, ≥65y: 50)
ID 9 μg 1 do se
Day 0 vaccinated : 100
(20-64y: 50,≥65y: 50)
ID 15 μg 1 dose
Day0 vaccina ted : 10 0
(20-64y: 50, ≥65y: 50)
Immunoge nisity
analysis: 10 0
Safety an alysis:  100
Immunoge nisity
analysis: 10 0
Safety an alysis:  100
Immunoge nisity
analysis: 10 0
Safety an alysis:  100
Immunoge nisity
analysis: 10 0
Safety an alysis:  100
Immunoge nisity
analysis: 10 0
Safety an alysis:  100
Immunoge nisity
analysis: 10 0
Safety an alysis:  100
Discontinu ation
Lost t o follow-up :0
SC  15 μg 1 do se
Day0 vaccina ted : 10 0
(20-64y: 50, ≥65y: 50)
ID 15 μg 2 do se
Day 0 vacc inated:  100
(20-64y: 50, ≥65y: 50)
Day21 vacc inated: 97
(20-64y: 48, ≥65y: 49)
SC 15 μg 2 do se
Day 0 vaccinated: 100
(20-64y: 50, ≥65y: 50)
Day21 vaccinated: 99
(20-64y: 49, ≥65y: 50)
Discontinu ation
Lost t o follow-up: 0
Discontinu ation
Lost to follow-up: 0
Discontinu ation
Lost to follow-up: 0
Discontinu ation
Lost t o follow-up: 0
Withd rew consen t: 1
(20-64 y)
Adverse event: 1
(20-64 y)
Investigator’s de cision : 1
(≥65y)
Discontinu ation
Lost t o follow-up: 0
Withd rew consen t: 1
(20-64 y)
600 subjects enrolled and rando mized
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ate (SPR, the percentage of subjects with HAI titer ≥1:40), the
eroconversion rate (SCR, the percentage of subjects with either
 pre-vaccination HAI titer <1:10 and post-vaccination HAI titer
1:40 or a pre-vaccination HAI titers ≥1:10 and at least a 4-
old increase in post-vaccination HAI titer), and the geometric
ean titer ratio (GMTR) of post-vaccination titer to pre-vaccination
iter of HAI [13]. NT titers were also assessed in the same way.
mmunogenicity was assessed in all subjects who received the vac-
ine.
.5. Safety assessment
Solicited injection-site AEs (erythema, swelling, pruritus, hot-
ess, pain, induration, and ecchymosis) and systemic AEs (malaise,
eadache, shivering, fever, and rash) were prelisted in the diary,
nd subjects were spontaneously checked every day up to 7 days
ollowing each vaccination. Unsolicited AEs and serious AEs (SAEs)
ere recorded throughout the study period (Days 0–21 for the
ingle-dose group; Days 0–42 for the two-dose group). The severity
f injection-site erythema, swelling, induration, and hemorrhage
as graded by size (long-axis diameter) as mild (<2.0 cm), mod-
rate (2.0–5.0 cm), or severe (>5.0 cm), while that of fever was
raded as mild (37.5–37.9 ◦C), moderate (38.0–38.9 ◦C), or severe
≥39.0 ◦C). All other AEs were classiﬁed as mild (for no interfer-
nce with daily activity and easily tolerated), moderate (for some
nterference with daily activity), or severe (for incapacitating con-
ition). Safety was assessed in all subjects who received the ﬁrst
accination.
.6. Statistical analysisA total of 600 healthy adult subjects were enrolled into this
tudy. The sample size was decided to be 50 subjects per subgroup
100 subjects per group with 50 for Young Adult subgroup and 50
or Older Adult subgroup). Statistical analyses were performed with
AS® version 9.2 (SAS Institute, Cary, NC, USA).mized into 6 groups.
3. Results
3.1. Study population
In April and May  2013, 600 subjects were enrolled. One hundred
subjects were assigned to each group (50 for the Young Adult sub-
group [20–64 years old] and 50 for the Older Adult subgroup [65
years old and older]) (Fig. 1). After the ﬁrst vaccination, 3 subjects
in the Young Adult subgroups had withdrawn. Among these, 2 sub-
jects had withdrawn voluntarily with one in the two-dose group
of ID 15 g HA and another in the two-dose group of SC 15 g HA,
while 1 subject had withdrawn due to moderate fever in the two-
dose group of ID 15 g HA. Also, after the ﬁrst vaccination, 1 subject
in the Older Adult subgroup had withdrawn in the two-dose group
of ID 15 g HA because the investigator suspected angina pectoris
and judged the subject as inadequate for continuing to join this
clinical study.
The demography of subjects in this study is shown in Table 1. The
distribution of age, the sex ratio, and the frequency of those having
history of seasonal inﬂuenza vaccination in the past two  seasons
(2011/12 and 2012/13) were comparable among the six vaccine
groups. The coverage rates of seasonal inﬂuenza vaccination in
Older Adult subgroups were higher than those in Young Adult sub-
groups. No subjects reported any history of seasonal inﬂuenza in
the 2012/13 season.
3.2. Immunogenicity
As shown in Table 2, the results of HAI titers in all ID vaccine
groups met  all parameters of the CHMP criteria for all three vaccine
strains, except for the SPRs for the B strain in the single-dose Young
Adult subgroup of ID 9 and ID 15 g HA.
Among the single-dose groups of ID 6, ID 9, and ID 15 g HA,
and SC 15 g HA, the GMTs and GMTRs of HAI and the SCRs and
SPRs of HAI titers for all three strains were the highest in the ID
15 g HA group on both Day 10 and Day 21, while the GMTRs of
HAI were comparable among the ID 6, and ID 9 g HA groups, and
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Table  1
Demography of the study subjects.
Total Single-dose group Two-dose group Total (n = 600)
ID 6 g (n = 100) ID 9 g (n = 100) ID 15 g (n = 100) SC 15 g (n = 100) ID 15 g (n = 100) SC 15 g (n = 100)
Sex, n (%)
Male 50 (50.0) 50 (50.0) 50 (50.0) 50 (50.0) 50 (50.0) 50 (50.0) 300 (50.0)
Female  50 (50.0) 50 (50.0) 50 (50.0) 50 (50.0) 50 (50.0) 50 (50.0) 300 (50.0)
Age,  years
Mean ± standard
deviation
51.5 ± 20.63 51.6 ± 20.58 51.5 ± 20.98 50.4 ± 21.50 51.3 ± 20.80 51.3 ± 21.05 51.3 ± 20.84
Range  20–80 20–79 20–79 20–79 20–81 20–81 20–81
History of inﬂuenza
vaccination,a n (%)
34 (34.0) 33 (33.0) 28 (28.0) 29 (29.0) 32 (32.0) 25 (25.0) 181 (30.2)
Young  adults (20–64
years)
Single- dose group Two-dose group Total (n = 300)
ID 6 g (n = 50) ID 9 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50)
Sex, n (%)
Male 25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 150 (50.0)
Female  25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 150 (50.0)
Age,  years
Mean ± standard
deviation
32.8 ± 11.48 32.8 ± 10.62 32.6 ± 12.19 30.9 ± 11.97 32.7 ± 12.42 32.6 ± 12.97 32.4 ± 11.89
Range  20–62 20–57 20–63 20–61 20–60 20–64 20–64
History of inﬂuenza
vaccination,a n (%)
5 (10.0) 7 (14.0) 3 (6.0) 2 (4.0) 2 (4.0) 5 (10.0) 24 (8.0)
Older  adults (65 years
and older)
Single-dose group Two-dose group Total (n = 300)
ID 6 g (n = 50) ID 9 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50)
Sex, n (%)
Male 25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 150 (50.0)
Female  25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 25 (50.0) 150 (50.0)
Age,  years
Mean ± standard
deviation
70.2 ± 3.90 70.5 ± 4.18 70.4 ± 3.85 69.9 ± 3.58 69.9 ± 3.69 69.9 ± 4.05 70.1 ± 3.86
Range  65–80 65–79 65–79 65–79 65–81 65–81 65–81
History of inﬂuenza
vaccination,a n (%)
29 (58.0) 26 (52.0) 25 (50.0) 27 (54.0) 30 (60.0) 20 (40.0) 157 (52.3)
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a Subjects who  have previously received an inﬂuenza vaccination in the past 2 se
bbreviation: n, number of subjects.
C 15 g HA groups. This suggested that the ID vaccine containing
5 g HA induced higher serum HAI titers as compared with the
tandard SC 15 g HA vaccine and further suggested that the ID
accines with a lower dose of HA, even as low as 6 g HA, induced
AI titers comparable with the standard SC 15 g HA vaccine.
The kinetics of the HAI titers after secondary vaccination on Day
1 showed that the boosting effect differed depending on the age
f the subjects, the types of the vaccines, and the strains of HA
ntigens. In Older Adult subgroups, the GMTRs of HAI on Day 42
nd Day 21 were comparable in the ID 15 g HA group except for
n the B strain (the ratio of GMTR of Day 42 to that of Day 21 (Strain,
MTR Day 42/GMTR Day 21: A/H1N1, 0.98; A/H3N2, 1.00; B, 1.14),
hile the GMTRs on Day 42 were higher than those on Day 21 in the
C 15 g HA group (Strain, GMTR Day 42/GMTR Day 21: A/H1N1,
.19; A/H3N2, 1.28; B, 1.27). By contrast, in Young Adult subgroups,
xcept for the B strain in the ID 15 g HA group, the GMTRs of
AI on Day 42 were comparable with those on Day 21 in both ID
5 g (Strain, GMTR Day 42/GMTR Day 21: A/H1N1, 1.09; A/H3N2,
.95; B, 1.14) and SC 15 g (Strain, GMTR Day 42/GMTR Day 21:
/H1N1, 1.07; A/H3N2, 1.07; B, 0.94) HA groups. Taken together,
t was suggested that the ID vaccine has the potential to elicit the
rompt immune response, which is rather hampered in older adults
s seen in HAI titers induced by the standard SC vaccine in this
tudy.
The SPRs for the H1N1 and H3N2 strains in both ID 15 g
nd SC 15 g HA groups achieved more than 90% on Day 21. In (2011–2012, 2012–2013).
contrast, the highest difference of the SPRs between the groups of
ID 15 g and SC 15 g HA was seen in the B strain in Older Adult
subgroups (the SPR in the ID group versus that in the SC group [SPR
ID vs SC] on Day 21: 62.00% vs 30.00% in the Older Adult subgroup,
while 80.00% vs 78.00% in the Young Adult subgroup; SPR ID vs SC
on Day 42: 69.39% vs 48.00% in the Older Adult subgroup, while
83.33% vs 75.51% in the Young Adult subgroup), suggesting that
the advantages of the ID vaccine are apparent in subtype antigens
showing lower immunogenicity, i.e., the B strain of inﬂuenza HA,
and in lower responders, i.e., the elderly.
The results of NT titers are shown in Table 3. As compared with
HAI, the GMTRs of NT were lower, which may  be due to a higher
titer value in NT than that in HAI on Day 0 except for the H3N2
strain in Older Adult subgroups. The pattern of post-vaccination
titer kinetics of NT was similar to that of HAI.
3.3. Safety
At least one unsolicited AE was  reported in 531 subjects (in the
single-dose groups: ID 6 g, 94% [94/100]; ID 9 g, 96% [96/100];
ID 15 g, 93% [93/100]; SC 15 g, 72% [72/100]; in the two-dose
groups: ID 15 g, 96% [96/100]; SC 15 g, 80% [80/100]). No imme-
diate AEs, such as shock and anaphylaxy, were reported.
The frequencies of solicited injection-site AEs or systemic AEs
are shown in Table 4. The most frequently reported AEs in all
groups were erythema, swelling, and pruritus at injection sites.
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Table 2.1
Serological efﬁcacy of hemagglutination inhibition antibody titer (young adults (20–64 years old)).
Strain Immunogenicity criteriaa Day Single-dose group Two-dose group
ID 6 g (n = 50) ID 9 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50)
A/H1N1
GMT  (95% CI) –
0 20.4 (12.4, 33.3) 27.2 (16.6, 44.8) 18.0 (11.1, 29.3) 23.1 (13.9, 38.6) 24.6 (14.9, 40.7) 35.7 (20.3, 62.7)
10  199.7 (122.8, 324.8) 362.5 (245.1, 536.2) 624.7 (449.9, 867.3) 206.8 (131.5, 325.1) – –
21  399.5 (268.2, 595.0) 568.9 (405.9, 797.2) 796.2 (652.1, 972.1) 437.1 (310.4, 615.7) 956.7 (826.2, 1107.9) (n = 48) 543.8 (412.1, 717.5) (n = 49)
42  – – – – 938.4 (821.3, 1072.2) 604.8 (496.9, 736.2)
SCR,  % (95% CI) >40%
10 58.0 (43.2, 71.8) 74.0 (59.7, 85.4) 90.0 (78.2, 96.7) 58.0 (43.2, 71.8) – –
21  80.0 (66.3, 90.0) 84.0 (70.9, 92.8) 94.0 (83.5, 98.8) 74.0 (59.7, 85.4) 92.0 (80.8, 97.8) 74.0 (59.7, 85.4)
42  – – – – 95.8 (85.8, 99.5) 81.6 (68.0, 91.2)
GMTR  (95% CI) >2.5
10 9.8 (5.0, 19.4) 13.3 (7.1, 24.9) 34.7 (19.4, 61.8) 8.9 (4.6, 17.6) – –
21  19.6 (10.5, 36.7) 20.9 (11.5, 37.8) 44.2 (26.3, 74.1) 18.9 (10.3, 34.7) 38.9 (23.2, 65.1) 15.2 (8.2, 28.3)
42  – – – – 42.4 (25.5, 70.6) 16.3 (9.0, 29.5)
SPR,  % (95% CI) >70%
10 86.0 (73.3, 94.2) 94.0 (83.5, 98.8) 96.0 (86.3, 99.5) 88.0 (75.7, 95.5) – –
21  94.0 (83.5, 98.8) 96.0 (86.3, 99.5) 100.0 (92.9, 100.0) 96.0 (86.3, 99.5) 100.0 (92.9, 100.0) 98.0 (89.4, 100.0)
42  – – – – 100.0 (92.6, 100.0) 100.0 (92.8, 100.0)
A/H3N2
GMT  (95% CI) –
0 41.0 (24.5, 68.6) 35.1 (20.7, 59.3) 27.9 (16.4, 47.5) 26.6 (16.1, 44.0) 21.2 (13.0, 34.6) 45.0 (25.7, 78.8)
10  259.9 (170.6, 396.1) 307.0 (205.7, 458.1) 340.6 (229.2, 506.3) 127.3 (79.9, 202.7) – –
21  466.9 (314.7, 692.7) 495.2 (357.4, 686.3) 462.1 (343.4, 621.7) 251.1 (169.3, 372.4) 505.6 (392.4, 651.6) 396.7 (306.8, 513.0)
42  – – – – 508.0 (401.5, 642.6) 443.1 (354.2, 554.2)
SCR,  % (95% CI) >40%
10 56.0 (41.3, 70.0) 58.0 (43.2, 71.8) 70.0 (55.4, 82.1) 44.0 (30.0, 58.8) – –
21  66.0 (51.2, 78.8) 70.0 (55.4, 82.1) 82.0 (68.6, 91.4) 62.0 (47.2, 75.4) 80.0 (66.3, 90.0) 64.0 (49.2, 77.1)
42  – – – – 79.2 (65.0, 89.5) 63.3 (48.3, 76.6)
GMTR  (95% CI) >2.5
10 6.3 (3.3, 12.2) 8.8 (4.6, 16.8) 12.2 (6.3, 23.5) 4.8 (2.4, 9.4) – –
21  11.4 (6.0, 21.6) 14.1 (7.7, 26.0) 16.6 (9.1, 30.3) 9.4 (5.0, 17.8) 23.8 (13.8, 41.0) 8.8 (4.8, 16.2)
42  – – – – 22.5 (13.0, 39.0) 9.4 (5.2, 17.1)
SPR,  % (95% CI) >70%
10 92.0 (80.8, 97.8) 94.0 (83.5, 98.8) 94.0 (83.5, 98.8) 84.0 (70.9, 92.8) – –
21  94.0 (83.5, 98.8) 98.0 (89.4, 100.0) 98.0 (89.4, 100.0) 92.0 (80.8, 97.8) 100.0 (92.9, 100.0) 100.0 (92.9, 100.0)
42  – – – – 100.0 (92.6, 100.0) 100.0 (92.8, 100.0)
B
GMT  (95% CI) –
0 9.0 (7.1, 11.6) 8.4 (6.4, 10.9) 7.0 (5.6, 8.7) 10.6 (7.9, 14.4) 10.4 (8.0, 13.5) 9.7 (7.2, 12.9)
10  23.6 (16.1, 34.6) 22.4 (15.2, 32.8) 24.6 (16.5, 36.8) 19.2 (13.1, 28.0) – –
21  47.9 (32.4, 70.7) 38.4 (24.8, 59.5) 44.7 (28.4, 70.4) 47.9 (30.4, 75.5) 48.1 (34.3, 67.4) 43.8 (30.3, 63.2)
42  – – – – 55.0 (39.1, 77.2) 41.6 (28.8, 60.1)
SCR,  % (95% CI) >40%
10 34.0 (21.2, 48.8) 30.0 (17.9, 44.6) 44.0 (30.0, 58.8) 22.0 (11.5, 36.0) – –
21  58.0 (43.2, 71.8) 52.0 (37.4, 66.3) 66.0 (51.2, 78.8) 50.0 (35.5, 64.5) 62.0 (47.2, 75.4) 56.0 (41.3, 70.0)
42  – – – – 68.8 (53.8, 81.3) 57.1 (42.2, 71.2)
GMTR  (95% CI) >2.5
10 2.6 (1.7, 4.1) 2.7 (1.7, 4.2) 3.5 (2.2, 5.6) 1.8 (1.1, 2.9) – –
21  5.3 (3.4, 8.4) 4.6 (2.8, 7.6) 6.4 (3.9, 10.6) 4.5 (2.6, 7.7) 4.6 (3.0, 7.1) 4.5 (2.9, 7.2)
42  – – – – 5.3 (3.5, 8.1) 4.2 (2.7, 6.8)
SPR,  % (95% CI) >70%
10 52.0 (37.4, 66.3) 50.0 (35.5, 64.5) 52.0 (37.4, 66.3) 48.0 (33.7, 62.6) – –
21  76.0 (61.8, 86.9) 68.0 (53.3, 80.5) 68.0 (53.3, 80.5) 68.0 (53.3, 80.5) 80.0 (66.3, 90.0) 78.0 (64.0, 88.5)
42  – – – – 83.3 (69.8, 92.5) 75.5 (61.1, 86.7)
a The European Union Committee for Medicinal Products forHuman Use (CHMP) criteria deﬁned for people aged ≤60.
Abbreviations:  GMT, geometric mean titer; SCR, seroconversion rate (proportion with a pre-vaccination titer <1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in
post-vaccination titer); GMTR, geometric mean titer ratio; SPR, seroprotection rate (percentage of participants with a post-vaccination titer ≥1:40); CI, conﬁdence interval.
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Table 2.2
Serological efﬁcacy of hemagglutination inhibition antibody titer (older adults (65 years and older)).
Strain Immunogenicity criteriaa Day Single-dose group Two-dose group
ID 6 g (n = 50) ID 9 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50)
A/H1N1
GMT (95% CI) –
0 31.4 (17.9, 54.9) 47.4 (27.7, 81.2) 35.1 (19.9, 61.9) 31.2 (17.8, 54.5) 31.6 (17.8, 56.1) 25.6 (15.0, 43.7)
10  224.7 (142.5, 354.4) 185.1 (110.7, 309.3) 295.5 (197.4, 442.3) 189.0 (130.6, 273.5) – –
21  310.2 (202.3, 475.5) 310.2 (218.4, 440.5) 447.9 (337.2, 594.8) 311.3 (223.4, 433.7) 425.2 (317.2, 569.9) (n = 49) 197.7 (134.3, 290.9)
42  – – – – 430.7 (322.0, 576.1) 234.3 (165.7, 331.1)
SCR,  % (95% CI) >30%
10 54.0 (39.3, 68.2) 38.0 (24.7, 52.8) 56.0 (41.3, 70.0) 54.0 (39.3, 68.2) – –
21  60.0 (45.2, 73.6) 56.0 (41.3, 70.0) 66.0 (51.2, 78.8) 58.0 (43.2, 71.8) 72.0 (57.5, 83.8) 56.0 (41.3, 70.0)
42  – – – – 73.5 (58.9, 85.1) 64.0 (49.2, 77.1)
GMTR  (95% CI) >2.0
10 7.2 (3.5, 14.6) 3.9 (1.9, 8.1) 8.4 (4.2, 16.8) 6.1 (3.1, 11.8) – –
21  9.9 (4.9, 19.8) 6.5 (3.5, 12.3) 12.8 (6.8, 23.9) 10.0 (5.3, 19.0) 13.5 (7.1, 25.4) 7.7 (4.0, 14.8)
42  – – – – 13.1 (6.9, 24.9) 9.2 (4.9, 17.2)
SPR,  % (95% CI) >60%
10 88.0 (75.7, 95.5) 84.0 (70.9, 92.8) 92.0 (80.8, 97.8) 94.0 (83.5, 98.8) – –
21  92.0 (80.8, 97.8) 96.0 (86.3, 99.5) 98.0 (89.4, 100.0) 96.0 (86.3, 99.5) 98.0 (89.4, 100.0) 90.0 (78.2, 96.7)
42  – – – – 98.0 (89.2, 100.0) 94.0 (83.5, 98.8)
A/H3N2
GMT  (95% CI) –
0 88.2 (51.2, 151.9) 95.1 (55.7, 162.7) 56.0 (31.5, 99.4) 77.5 (42.9, 140.0) 77.8 (44.8, 135.2) 42.9 (25.0, 73.6)
10  274.7 (175.9, 429.1) 294.5 (183.7, 472.1) 399.5 (287.9, 554.2) 245.1 (164.2, 365.6) – –
21  475.1 (359.8, 627.2) 502.1 (370.5, 680.5) 505.6 (391.1, 653.6) 329.0 (226.8, 477.3) 481.7 (355.6, 652.5) 251.1 (163.0, 386.7)
42  – – – – 510.4 (388.1, 671.1) 322.2 (224.1, 463.4)
SCR,  % (95% CI) >30%
10 34.0 (21.2, 48.8) 32.0 (19.5, 46.7) 56.0 (41.3, 70.0) 34.0 (21.2, 48.8) – –
21  50.0 (35.5, 64.5) 44.0 (30.0, 58.8) 68.0 (53.3, 80.5) 42.0 (28.2, 56.8) 48.0 (33.7, 62.6) 50.0 (35.5, 64.5)
42  – – – – 49.0 (34.4, 63.7) 60.0 (45.2, 73.6)
GMTR  (95% CI) >2.0
10 3.1 (1.6, 6.2) 3.1 (1.5, 6.3) 7.1 (3.7, 13.7) 3.2 (1.6, 6.4) – –
21  5.4 (2.9, 9.9) 5.3 (2.9, 9.7) 9.0 (4.9, 16.8) 4.2 (2.1, 8.5) 6.2 (3.3, 11.5) 5.9 (3.0, 11.6)
42  – – – – 6.2 (3.4, 11.4) 7.5 (4.0, 14.3)
SPR,  % (95% CI) >60%
10 90.0 (78.2, 96.7) 90.0 (78.2, 96.7) 98.0 (89.4, 100.0) 94.0 (83.5, 98.8) – –
21  100.0 (92.9, 100.0) 98.0 (89.4, 100.0) 100.0 (92.9, 100.0) 96.0 (86.3, 99.5) 96.0 (86.3, 99.5) 94.0 (83.5, 98.8)
42  – – – – 98.0 (89.2, 100.0) 96.0 (86.3, 99.5)
B
GMT  (95% CI) –
0 8.7 (6.5, 11.6) 10.6 (8.2, 13.9) 9.5 (7.1, 12.6) 8.0 (6.2, 10.4) 10.3 (7.7, 13.7) 7.2 (5.9, 8.8)
10  20.7 (13.9, 30.8) 21.6 (15.4, 30.2) 21.6 (14.6, 32.0) 14.1 (9.9, 20.0) – –
21  26.9 (18.1, 40.1) 31.2 (21.7, 44.8) 31.4 (20.9, 47.2) 19.5 (12.7, 29.7) 30.3 (21.2, 43.3) 13.8 (9.8, 19.4)
42  – – – – 35.0 (24.5, 50.0) 17.5 (12.3, 25.0)
SCR,  % (95% CI) >30%
10 36.0 (22.9, 50.8) 26.0 (14.6, 40.3) 40.0 (26.4, 54.8) 16.0 (7.2, 29.1) – –
21  48.0 (33.7, 62.6) 42.0 (28.2, 56.8) 56.0 (41.3, 70.0) 30.0 (17.9, 44.6) 42.0 (28.2, 56.8) 28.0 (16.2, 42.5)
42  – – – – 51.0 (36.3, 65.6) 40.0 (26.4, 54.8)
GMTR  (95% CI) >2.0
10 2.4 (1.5, 3.9) 2.0 (1.3, 3.1) 2.3 (1.4, 3.7) 1.8 (1.1, 2.7) – –
21  3.1 (1.9, 5.1) 2.9 (1.9, 4.6) 3.3 (2.0, 5.4) 2.4 (1.5, 4.0) 3.0 (1.9, 4.7) 1.9 (1.3, 2.8)
42  – – – – 3.4 (2.1, 5.3) 2.4 (1.6, 3.6)
SPR,  % (95% CI) >60%
10 52.0 (37.4, 66.3) 54.0 (39.3, 68.2) 50.0 (35.5, 64.5) 28.0 (16.2, 42.5) – –
21  62.0 (47.2, 75.4) 66.0 (51.2, 78.8) 66.0 (51.2, 78.8) 40.0 (26.4, 54.8) 62.0 (47.2, 75.4) 30.0 (17.9, 44.6)
42  – – – – 69.4 (54.6, 81.8) 48.0 (33.7, 62.6)
a The European Union Committee for Medicinal Products for Human Use (CHMP) criteria deﬁned for people aged >60.
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Table 3.1
Serological efﬁcacy of neutralization antibody titer (young adults).
Strain Day Single-dose group Two-dose group
ID 6 g (n = 50) ID 9 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50)
A/H1N1
GMT  (95% CI)
0 29.7 (21.3, 41.5) 31.8 (23.0, 44.1) 28.3 (19.5, 41.1) 38.1 (26.6, 54.6) 25.7 (18.7, 35.3) 39.7 (27.9, 56.5)
10  150.3 (112.0, 201.8) 181.3 (142.8, 230.1) 158.9 (122.3, 206.5) 136.4 (99.6, 186.8) – –
21  251.1 (207.4, 303.9) 254.6 (210.9, 307.3) 249.3 (205.8, 302.1) 226.3 (182.6, 280.4) 173.9 (145.3, 208.1) 160.0 (128.5, 199.2)
42  – – – – 190.3 (161.0, 224.9) 162.3 (131.1, 200.8)
SCR,  % (95% CI)
10 54.0 (39.3, 68.2) 62.0 (47.2, 75.4) 60.0 (45.2, 73.6) 42.0 (28.2, 56.8) – –
21  74.0 (59.7, 85.4) 70.0 (55.4, 82.1) 76.0 (61.8, 86.9) 60.0 (45.2, 73.6) 70.0 (55.4, 82.1) 38.0 (24.7, 52.8)
42  – – – – 75.0 (60.4, 86.4) 36.7 (23.4, 51.7)
GMTR  (95% CI)
10 5.1 (3.3, 7.9) 5.7 (3.8, 8.5) 5.6 (3.6, 8.8) 3.6 (2.2, 5.7) – –
21  8.5 (5.8, 12.4) 8.0 (5.5, 11.6) 8.8 (5.8, 13.4) 5.9 (3.9, 9.0) 6.8 (4.7, 9.7) 4.0 (2.7, 6.1)
42  – – – – 7.7 (5.3, 11.0) 4.1 (2.7, 6.2)
SPR,  % (95% CI)
10 90.0 (78.2, 96.7) 94.0 (83.5, 98.8) 88.0 (75.7, 95.5) 84.0 (70.9, 92.8) – –
21  98.0 (89.4, 100.0) 100.0 (92.9, 100.0) 98.0 (89.4, 100.0) 96.0 (86.3, 99.5) 98.0 (89.4, 100.0) 96.0 (86.3, 99.5)
42  – – – – 100.0 (92.6, 100.0) 98.0 (89.2, 100.0)
A/H3N2
GMT  (95% CI)
0 50.3 (39.6, 63.8) 44.7 (33.7, 59.3) 40.8 (31.3, 53.3) 36.3 (29.5, 44.7) 32.0 (25.4, 40.4) 36.6 (28.1, 47.6)
10  118.8 (93.3, 151.2) 146.2 (114.1, 187.4) 129.1 (100.9, 165.1) 87.5 (69.0, 111.1) – –
21  192.9 (154.3, 241.3) 192.9 (153.2, 242.9) 195.6 (158.6, 241.3) 130.0 (101.7, 166.1) 124.7 (98.9, 157.1) 85.7 (68.6, 107.1)
42  – – – – 135.5 (108.4, 169.5) 120.6 (98.8, 147.1)
SCR,  % (95% CI)
10 24.0 (13.1, 38.2) 42.0 (28.2, 56.8) 46.0 (31.8, 60.7) 24.0 (13.1, 38.2) – –
21  50.0 (35.5, 64.5) 58.0 (43.2, 71.8) 66.0 (51.2, 78.8) 40.0 (26.4, 54.8) 48.0 (33.7, 62.6) 24.0 (13.1, 38.2)
42  – – – – 54.2 (39.2, 68.6) 34.7 (21.7, 49.6)
GMTR  (95% CI)
10 2.4 (1.7, 3.3) 3.3 (2.3, 4.7) 3.2 (2.2, 4.5) 2.4 (1.8, 3.3) – –
21  3.8 (2.8, 5.3) 4.3 (3.0, 6.2) 4.8 (3.4, 6.7) 3.6 (2.6, 4.9) 3.9 (2.8, 5.4) 2.3 (1.7, 3.3)
42  – – – – 4.2 (3.0, 5.8) 3.2 (2.3, 4.5)
SPR,  % (95% CI)
10 90.0 (78.2, 96.7) 94.0 (83.5, 98.8) 90.0 (78.2, 96.7) 84.0 (70.9, 92.8) – –
21  94.0 (83.5, 98.8) 98.0 (89.4, 100.0) 96.0 (86.3, 99.5) 86.0 (73.3, 94.2) 94.0 (83.5, 98.8) 86.0 (73.3, 94.2)
42  – – – – 95.8 (85.8, 99.5) 95.9 (86.0, 99.5)
B
GMT  (95% CI)
0 40.3 (30.4, 53.4) 28.7 (21.1, 39.0) 28.9 (22.9, 36.5) 32.3 (24.5, 42.6) 30.1 (21.5, 42.2) 30.5 (22.4, 41.5)
10  84.6 (64.3, 111.3) 70.1 (52.0, 94.6) 71.1 (54.3, 93.0) 60.2 (44.8, 81.0) – –
21  148.3 (118.0, 186.2) 102.0 (79.3, 131.2) 104.1 (80.9, 134.0) 92.5 (70.3, 121.8) 102.7 (79.1, 133.3) 97.8 (78.9, 121.2)
42  – – – – 177.0 (146.9, 213.4) 145.9 (120.3, 177.1)
SCR,  % (95% CI)
10 22.0 (11.5, 36.0) 22.0 (11.5, 36.0) 32.0 (19.5, 46.7) 12.0 (4.5, 24.3) – –
21  48.0 (33.7, 62.6) 48.0 (33.7, 62.6) 48.0 (33.7, 62.6) 38.0 (24.7, 52.8) 52.0 (37.4, 66.3) 46.0 (31.8, 60.7)
42  – – – – 75.0 (60.4, 86.4) 67.4 (52.5, 80.1)
GMTR  (95% CI)
10 2.1 (1.4, 3.1) 2.4 (1.6, 3.7) 2.5 (1.7, 3.5) 1.9 (1.3, 2.8) – –
21  3.7 (2.6, 5.3) 3.6 (2.4, 5.3) 3.6 (2.6, 5.1) 2.9 (2.0, 4.2) 3.4 (2.2, 5.2) 3.2 (2.2, 4.6)
42  – – – – 5.5 (3.8, 8.1) 4.7 (3.3, 6.8)
SPR,  % (95% CI)
10 84.0 (70.9, 92.8) 66.0 (51.2, 78.8) 78.0 (64.0, 88.5) 58.0 (43.2, 71.8) – –
21  96.0 (86.3, 99.5) 86.0 (73.3, 94.2) 92.0 (80.8, 97.8) 80.0 (66.3, 90.0) 92.0 (80.8, 97.8) 94.0 (83.5, 98.8)
42  – – – – 97.9 (88.9, 100.0) 95.9 (86.0, 99.5)
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Table 3.2
Serological efﬁcacy of neutralization antibody titer (older adults).
Single-dose group Two-dose group
Strain Day ID 6 g (n = 50) ID 9 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50)
A/H1N1
GMT (95% CI)
0 33.2 (24.0, 45.9) 46.9 (32.0, 68.8) 44.4 (31.1, 63.3) 29.7 (21.8, 40.4) 47.6 (33.4, 67.8) 51.0 (35.8, 72.5)
10  106.3 (81.2, 139.2) 110.8 (83.4, 147.2) 144.2 (116.2, 178.9) 76.7 (56.5, 104.3) – –
21  110.0 (82.0, 147.6) 123.8 (95.5, 160.6) 162.2 (133.5, 197.2) 96.5 (71.9, 129.4) 134.5 (99.0, 182.8) 143.2 (110.5, 185.5)
42  – – – – 140.9 (103.3, 192.1) 149.3 (113.4, 196.5)
SCR,  % (95% CI)
10 34.0 (21.2, 48.8) 24.0 (13.1, 38.2) 38.0 (24.7, 52.8) 24.0 (13.1, 38.2) – –
21  44.0 (30.0, 58.8) 32.0 (19.5, 46.7) 44.0 (30.0, 58.8) 34.0 (21.2, 48.8) 24.0 (13.1, 38.2) 22.0 (11.5, 36.0)
42  – – – – 26.5 (15.0, 41.1) 26.0 (14.6, 40.3)
GMTR  (95% CI)
10 3.2 (2.1, 4.9) 2.4 (1.5, 3.8) 3.2 (2.2, 4.9) 2.6 (1.7, 4.0) – –
21  3.3 (2.2, 5.1) 2.6 (1.7, 4.2) 3.7 (2.4, 5.5) 3.2 (2.1, 5.0) 2.8 (1.8, 4.5) 2.8 (1.8, 4.3)
42  – – – – 2.8 (1.8, 4.5) 2.9 (1.9, 4.6)
SPR,  % (95% CI)
10 82.0 (68.6, 91.4) 86.0 (73.3, 94.2) 96.0 (86.3, 99.5) 74.0 (59.7, 85.4) – –
21  84.0 (70.9, 92.8) 92.0 (80.8, 97.8) 98.0 (89.4, 100.0) 76.0 (61.8, 86.9) 88.0 (75.7, 95.5) 90.0 (78.2, 96.7)
42  – – – – 87.8 (75.2, 95.4) 88.0 (75.7, 95.5)
A/H3N2
GMT  (95% CI)
0 32.9 (23.5, 46.3) 37.6 (27.1, 52.2) 26.6 (19.5, 36.3) 33.2 (24.2, 45.4) 22.5 (16.8, 30.1) 17.3 (13.3, 22.5)
10  69.6 (49.2, 98.5) 85.7 (64.5, 113.9) 75.7 (54.2, 105.7) 59.8 (44.4, 80.6) – –
21  104.1 (76.6, 141.5) 113.9 (86.5, 150.0) 95.1 (68.6, 131.9) 78.4 (57.0, 107.7) 57.8 (41.6, 80.2) 40.8 (29.5, 56.5)
42  – – – – 65.6 (47.5, 90.6) 50.6 (36.2, 70.9)
SCR,  % (95% CI)
10 12.0 (4.5, 24.3) 24.0 (13.1, 38.2) 32.0 (19.5, 46.7) 16.0 (7.2, 29.1) – –
21  32.0 (19.5, 46.7) 40.0 (26.4, 54.8) 40.0 (26.4, 54.8) 30.0 (17.9, 44.6) 32.0 (19.5, 46.7) 26.0 (14.6, 40.3)
42  – – – – 34.7 (21.7, 49.6) 32.0 (19.5, 46.7)
GMTR  (95% CI)
10 2.1 (1.3, 3.4) 2.3 (1.5, 3.5) 2.8 (1.8, 4.5) 1.8 (1.2, 2.8) – –
21  3.2 (2.0, 5.0) 3.0 (2.0, 4.6) 3.6 (2.3, 5.6) 2.4 (1.5, 3.7) 2.6 (1.7, 4.0) 2.4 (1.6, 3.6)
42  – – – – 3.0 (1.9, 4.6) 2.9 (1.9, 4.5)
SPR,  % (95% CI)
10 64.0 (49.2, 77.1) 80.0 (66.3, 90.0) 72.0 (57.5, 83.8) 66.0 (51.2, 78.8) – –
21  76.0 (61.8, 86.9) 90.0 (78.2, 96.7) 76.0 (61.8, 86.9) 70.0 (55.4, 82.1) 60.0 (45.2, 73.6) 50.0 (35.5, 64.5)
42  – – – – 65.3 (50.4, 78.3) 58.0 (43.2, 71.8)
B
GMT  (95% CI)
0 19.6 (15.0, 25.6) 25.0 (18.8, 33.2) 18.5 (14.6, 23.5) 22.8 (16.3, 31.9) 28.5 (19.8, 41.1) 14.4 (10.9, 19.0)
10  48.2 (36.1, 64.5) 52.8 (39.8, 70.0) 57.4 (42.9, 76.7) 40.6 (29.5, 55.8) – –
21  66.8 (51.6, 86.5) 76.7 (59.0, 99.9) 84.6 (63.8, 112.0) 61.1 (44.8, 83.2) 75.7 (56.0, 102.2) 45.0 (33.8, 60.0)
42  – – – – 90.9 (65.0, 127.0) 53.1 (39.1, 72.3)
SCR,  % (95% CI)
10 30.0 (17.9, 44.6) 24.0 (13.1, 38.2) 34.0 (21.2, 48.8) 12.0 (4.5, 24.3) – –
21  40.0 (26.4, 54.8) 40.0 (26.4, 54.8) 54.0 (39.3, 68.2) 32.0 (19.5, 46.7) 36.0 (22.9, 50.8) 28.0 (16.2, 42.5)
42  – – – – 36.7 (23.4, 51.7) 36.0 (22.9, 50.8)
GMTR  (95% CI)
10 2.5 (1.7, 3.6) 2.1 (1.4, 3.1) 3.1 (2.1, 4.5) 1.8 (1.1, 2.8) – –
21  3.4 (2.4, 4.9) 3.1 (2.1, 4.5) 4.6 (3.2, 6.6) 2.7 (1.7, 4.2) 2.7 (1.7, 4.2) 3.1 (2.1, 4.6)
42  – – – – 3.1 (1.9, 5.2) 3.7 (2.4, 5.5)
SPR,  % (95% CI)
10 62.0 (47.2, 75.4) 62.0 (47.2, 75.4) 64.0 (49.2, 77.1) 52.0 (37.4, 66.3) – –
21  74.0 (59.7, 85.4) 78.0 (64.0, 88.5) 82.0 (68.6, 91.4) 64.0 (49.2, 77.1) 72.0 (57.5, 83.8) 50.0 (35.5, 64.5)
42  – – – – 77.6 (63.4, 88.2) 56.0 (41.3, 70.0)
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Table 4
Summary of solicited injection-site and systemic adverse events.
Single-dose group Two-dose group
ID 6 g (n = 100) ID 9 g (n = 100) ID 15 g (n = 100) SC 15 g (n = 100) ID 15 g (n = 100) SC 15 g (n = 100)
Any injection site reactions, n (%) 93 (93.0) 95 (95.0) 92 (92.0) 69 (69.0) 95 (95.0) 76 (76.0)
Solicited injection site reactions
Erythema 92 (92.0) 93 (93.0) 86 (86.0) 58 (58.0) 93 (93.0) 66 (66.0)
Swelling 59 (59.0) 50 (50.0) 52 (52.0) 36 (36.0) 61 (61.0) 49 (49.0)
Pruritus 33 (33.0) 45 (45.0) 44 (44.0) 31 (31.0) 56 (56.0) 47 (47.0)
Warmth 21 (21.0) 30 (30.0) 24 (24.0) 26 (26.0) 27 (27.0) 32 (32.0)
Pain  17 (17.0) 18 (18.0) 23 (23.0) 32 (32.0) 23 (23.0) 37 (37.0)
Induration 9 (9.0) 14 (14.0) 23 (23.0) 8 (8.0) 21 (21.0) 14 (14.0)
Ecchymosis 4 (4.0) 1 (1.0) 1 (1.0) 4 (4.0) 4 (4.0) 6 (6.0)
Any  systemic reactions, n (%) 18 (18.0) 22 (22.0) 18 (18.0) 15 (15.0) 19 (19.0) 26 (26.0)
Solicited systemic reactions
Malaise 9 (9.0) 15 (15.0) 11 (11.0) 14 (14.0) 15 (15.0) 19 (19.0)
Headache 13 (13.0) 10 (10.0) 10 (10.0) 4 (4.0) 6 (6.0) 10 (10.0)
Shivering 1 (1.0) 6 (6.0) 2 (2.0) 2 (2.0) 4 (4.0) 6 (6.0)
Fevera 0 (0.0) 1 (1.0) 1 (1.0) 0 (0.0) 2 (2.0) 1 (1.0)
0 (0.
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a Axillary temperature ≥37.5 ◦C.
ercentages are calculated as the number of participants reporting the event divide
njection-site erythema, swelling, and pruritus occurred more fre-
uently, while injection-site pain occurred less frequently in the
D vaccine groups than the SC vaccine groups. The frequencies of
olicited systemic AEs were comparable between the ID and the
C vaccine groups, with the most frequent ones being malaise and
eadache.
Among the single-dose ID vaccine groups with different dosages,
he frequencies of any AE were comparable and were not in a
ose-dependent fashion. In the two-dose ID vaccine group, the
requencies of any AE after the ﬁrst vaccination (93.0% [93/100])
ere comparable with those after the second vaccination (89.7%
87/97]). There were no apparent differences in the frequency of
ach AE between Young Adult and Older Adult subgroups (data not
hown).
The ratios of each grade of injection-site erythema, swelling,
nd induration are shown in Fig. 2. The ratios of severe erythema
nd severe swelling in the ID vaccine groups were lower than those
n the SC vaccine groups. The severe induration was observed in
he ID 6 and 9 g HA groups but not in the ID and SC 15 g HA
roups. Taken together, it was not suggested that the severity of
Es at the injection site depends on the number of doses or dosage
f the ID vaccine.
Injection-site AEs lasted for 4.8–8.4 days (the single-dose
roups: ID 6 g HA, 7.5 days; ID 9 g HA, 7.5 days; ID 15 g HA,
.3 days; SC 15 g HA, 4.8 days; the two-dose groups: ID 15 g HA,
.4 days; SC 15 g HA, 5.0 days). Although the injection-site AEs in
he ID vaccine groups persisted longer than those in the SC vaccine
roups, all AEs in the ID vaccine groups disappeared without any
edical treatment.
All solicited and unsolicited systemic AEs were classiﬁed as mild
r moderate except immunoglobulin A nephropathy. Three sub-
ects experienced a total of four SAEs, and one SAE, immunoglobulin
 nephropathy, in the ID 6 g HA vaccine group was  considered
elated to the vaccination. One subject in the two-dose ID 15 g
A group withdrew due to moderate fever that occurred on Day 4.
. Discussion
In this study, it was suggested that the immunologic proﬁle of
he ID vaccine is better than that of the SC vaccine, while safety pro-
le of the ID vaccine is similar to that of the SC vaccine. In this phase
/2 study conducted with almost 100 subjects per each group, by
omparing with the standard SC injection type seasonal inﬂuenza
accine, the novel ID vaccine containing 15 g HA was  clinically0) 0 (0.0) 1 (1.0) 0 (0.0)
he number of subjects.
demonstrated to induce faster serum antibody responses and the
higher responses were maintained during the examination period
up to 42 days after the ﬁrst vaccination. The results in all the ID vac-
cine groups, including those even in the subgroup of Young Adult
or Older Adult, met  CHMP criteria for all three vaccine strains and
were well tolerated. It was therefore suggested that the ID vaccine
containing 15 g HA per dose per strain with a single or two-dose
regimen is appropriate for clinical use as a novel seasonal inﬂuenza
vaccine, and with an expectation of a superior protection against
inﬂuenza and the reduction of the disease burden.
The SCRs and GMTRs in the single-dose groups of ID 6, and 9 g,
and SC 15 g HA were comparable, suggesting that dose-sparing
can be expected by shifting from the standard SC vaccine to the ID
vaccine for cost-reduction and securing vaccine supply.
High antibody responses by the ID vaccine observed in this
clinical study imply that the novel ID injection system delivered
the vaccine formulation to the dermis accurately and consistently.
According to previous reports, it has been demonstrated that the
thickness of the skin varies marginally depending on age, sex, and
race, while that varies signiﬁcantly depending on the local site of
the body, e.g., the skin is thicker in the supracapsular and the del-
toid areas as compared with in the forearm area [14,15]. The ID
injection system used in this study has a needle 1.15 mm in length
inserting perpendicularly into the skin. The needle length is spe-
cially designed based on the skin thickness studies to stay the
proper depth for ID injection [14,15]. In fact, even though it was
not designated in the clinical study protocol, a preliminary obser-
vation of the wheal formation and absence of ﬂuid leakage at the
injection site, which are deﬁned as the criteria for successful ID
injection [16], was  conducted. As a result, the frequencies of the
injection-site wheal formation soon after the ID vaccination were
96.4% and 98.0% in Young Adult and Older Adult subgroups, respec-
tively and no leakage was observed in this study. The results of
previous clinical studies using different types of ID devices or using
a standard syringe and needle (the Mantoux technique) suggest
that the frequencies of the successful ID delivery were lower than
those observed in this study [16–18]. The novel ID injection sys-
tem is designed simple enough to handle easily and is expected to
reduce risks of damaging tissues, such as blood vessels and periph-
eral nerves, due to its thin and short needle.The safety proﬁle of our ID vaccine in this phase 1/2 study with
497 injections of the ID vaccine was  similar to those of other types of
ID vaccines as investigated in previous studies [16,19–25]. The fre-
quencies of most AEs at the injection site in the ID vaccine groups
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Fig. 2. The bar chart shows the percentage of each severity in the AE.
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ere higher than the SC vaccine groups, although injection-site
Es were generally mild, transient, and did not occur in a dose
r dosage-dependent manner. The safety proﬁle in Older Adult
ubgroups was comparable with that in Young Adult subgroups.
he high incidence rate of the injection-site AEs may  be because
he vaccine-induced inﬂammatory reactions that occurred in the
ermis, i.e., the antigen-delivery site of the ID vaccine, are more
etectable from the skin surface as compared with those in the
ubcutis. Our in-house study using an animal model has suggested
hat although the changes of inﬂammatory reactions examined by
he histopathological analysis were similar between the ID dos-
ng and the SC dosing of the same amount of inﬂuenza HA, the local
rritation scores examined based on the appearance of the skin were
igher after the ID dosing than after the SC dosing (data not shown).
aken together, it is suggested that the safety of the novel ID vac-
ine is secured in adults aged 20 years and older, at least in this
xploratory clinical study.
. Conclusions
In this exploratory study with almost 100 subjects per each
roup, we found that the novel ID vaccine containing 15 g HA
nduced serum antibody responses higher than the standard SC
accine containing 15 g HA, and its safety was well tolerated, sug-
esting that a single or two-dose of the ID vaccine with a dose of
5 g HA is an appropriate regimen for clinical use in order to pro-
ect from inﬂuenza infection and to reduce the associated disease
urden.
cknowledgement
The authors thank all members involved in R&D of the intrader-
al  vaccine in Terumo Co., Kitasato Daiichi Sankyo Vaccine Co., Ltd,
nd Daiichi Sankyo Co., Ltd. T.N. has received research funding from
aiichi Sankyo Co., Ltd and has previously participated at advisory
oard meetings sponsored by Daiichi Sankyo Co., Ltd.
eferences
[1] WHO  Fact sheet. http://www.who.int/mediacentre/factsheets/fs211/en/.
[2]  Houser K, Subbarao K. Inﬂuenza vaccines: challenges and solutions. Cell Host
Microbe 2015;17:295–300.
[3] Goodwin K, Viboud C, Simonsen L. Antibody response to inﬂuenza vaccination
in the elderly: a quantitative review. Vaccine 2006;24:1159–69.
[4] Icardi G, Orsi A, Ceravolo A, Ansaldi F. Current evidence on intradermal
inﬂuenza vaccines administered by Soluvia licensed micro injection system.
Hum Vaccin Immunother 2012;8:67–75.[5] Reisinger KS, Holmes SJ, Pedotti P, Arora AK, Lattanzi M.  A dose-ranging study of
MF59((R))-adjuvanted and non-adjuvanted A/H1N1 pandemic inﬂuenza vac-
cine in young to middle-aged and older adult populations to assess safety,
immunogenicity, and antibody persistence one year after vaccination. Hum
Vaccin Immunother 2014;10:2395–407.
[3 (2015) 6340–6350
[6] McElhaney JE, Beran J, Devaster JM,  Esen M,  Launay O,  Leroux-Roels G, et al.
AS03-adjuvanted versus non-adjuvanted inactivated trivalent inﬂuenza vac-
cine  against seasonal inﬂuenza in elderly people: a phase 3 randomised trial.
Lancet Infect Dis 2013;13:485–96.
[7] Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from
immunology to clinical practice. Expert Rev Vaccines 2008;7:1201–14.
[8] WHO  recommendations on Rabies post-exposure treatment and the cor-
rect technique of intradermal immunization against rabies. WHO/EMC/ZOO/
9661996. http://whqlibdoc.who.int/hq/1996/WHO EMC  ZOO 96.6.pdf.
[9] Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, et al. Evalua-
tion  of the clinical performance of a new intradermal vaccine administration
technique and associated delivery system. Vaccine 2007;25:8833–42.
10] Levin Y, Kochba E, Hung I, Kenney R. Intradermal vaccination using the novel
microneedle device MicronJet600: past, present, and future. Hum Vaccin
Immunother 2015;11:991–7.
11] Norman JJ, Gupta J, Patel SR, Park S, Jarrahian C, Zehrung D, et al. Reliability and
accuracy of intradermal injection by Mantoux technique, hypodermic needle
adapter, and hollow microneedle in pigs. Drug Deliv Transl Res 2014;4:126–30.
12] Tsals I, Jarrahian C, Snyder FE, Saganic L, Saxon E, Zehrung D, et al. Clinical
performance and safety of adapters for intradermal delivery with conventional
and autodisable syringes. Vaccine 2015;33:4705–11.
13] EMA  inﬂuenza vaccine guideline. http://www.ema.europa.eu/ema/pages/
includes/document/open document.jsp?webContentId=WC500003945.
14] Laurent A, Mistretta F, Bottigioli D, Dahel K, Goujon C, Nicolas JF, et al. Echo-
graphic measurement of skin thickness in adults by high frequency ultrasound
to assess the appropriate microneedle length for intradermal delivery of vac-
cines. Vaccine 2007;25:6423–30.
15] Saitoh A, Aizawa Y, Sato I, Hirano H, Sakai T, Mori M.  Skin thickness of young
infants and adolescents: application for intradermal vaccination in infants and
children. Vaccine 2015;33:3384–91.
16] Intanza assessment report. http:// www. ema.europa. eu/ema/ index.jsp?curl=
pages/ medicines/ human/ medicines/ 000957/ human med 000842. jsp&
mid=WC0b01ac058001d124.
17] Tarnow K, King N. Intradermal injections: traditional bevel up versus bevel
down. Appl Nurs Res 2004;17:275–82.
18] Hung IFN, Levin Y, To KKW, Chan KH, Zhang AJ, Li P, et al. Dose sparing
intradermal trivalent inﬂuenza (2010/2011) vaccination overcomes reduced
immunogenicity of the 2009 H1N1 strain. Vaccine 2012;30:6427–35.
19] Moro PL, Harrington T, Shimabukuro T, Cano M,  Museru OI,  Menschik D, et al.
Adverse events after Fluzone (R) Intradermal vaccine reported to the Vac-
cine  Adverse Event Reporting System (VAERS), 2011–2013. Vaccine 2013;31:
4984–7.
20] Leroux-Roels I, Vets E, Freese R, Seiberling M,  Weber F, Salamand C, et al. Sea-
sonal inﬂuenza vaccine delivered by intradermal microinjection: a randomised
controlled safety and immunogenicity trial in adults. Vaccine 2008;26:6614–9.
21] Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, et al.
Intradermal inﬂuenza vaccination of healthy adults using a new microinjection
system: a 3-year randomised controlled safety and immunogenicity trial. BMC
Med  2009;7:13.
22] Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP,  Weber F. Immunogenicity,
large scale safety and lot consistency of an intradermal inﬂuenza vaccine in
adults aged 18–60 years: randomized, controlled, phase III trial. Hum Vaccin
2010;6:346–54.
23] Frenck Jr RW,  Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, et al. Com-
parison of the immunogenicity and safety of a split-virion, inactivated, trivalent
inﬂuenza vaccine (Fluzone(R)) administered by intradermal and intramuscular
route in healthy adults. Vaccine 2011;29:5666–74.
24] Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intra-
dermal inﬂuenza vaccine administered using a new microinjection system
produces superior immunogenicity in elderly adults: a randomized controlled
trial. J Infect Dis 2008;198:650–8.
25] Arnou R, Icardi G, De Decker M,  Ambrozaitis A, Kazek MP,  Weber F, et al. Intra-
dermal inﬂuenza vaccine for older adults: a randomized controlled multicenter
phase III study. Vaccine 2009;27:7304–12.
